FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to medicine, namely to therapy and neurology, and deals with the treatment or prevention of pain. For this purpose dexmedetomidine is introduced on the mucous membrane of the oral cavity in a dose of 0.05-1.50 mcg/kg.
EFFECT: method of the medication introduction in the mentioned doses ensures an expressed analgesic effect with an insignificant sedative effect, namely the sedative effect for an hour after the introduction of dexmedetomidine is at the level of not higher than 2 by the Ramsay scale of sedative effect.
21 cl, 20 dwg, 5 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| INTRANASAL DEXMEDETOMIDINE COMPOSITIONS AND METHODS OF USE THEREOF | 2012 |
|
RU2692245C2 |
| METHOD FOR TREATING OR PREVENTING HYPOTENSION AND SHOCK | 2000 |
|
RU2259827C2 |
| COMPOSITIONS CONTAINING TRIPTANE COMPOUNDS | 2010 |
|
RU2710372C2 |
| TRANSMUCOSAL SYSTEM OF DELIVERY OF MEDICAL PRODUCTS | 2004 |
|
RU2342953C2 |
| COMPOSITIONS CONTAINING TRIPTANE COMPOUNDS | 2019 |
|
RU2762725C2 |
| NEW COMPOSITIONS AND METHODS | 2018 |
|
RU2767410C2 |
| SUBLINGUAL COATED TABLET | 2006 |
|
RU2403043C2 |
| VETERINARY METHOD FOR NOISE AVERSION REDUCTION | 2013 |
|
RU2638804C2 |
| IMMEDIATE-ACTION PHARMACEUTICAL COMPOSITION | 2004 |
|
RU2345791C2 |
| (R)-PIRLINDOLE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS FOR USE IN MEDICINE | 2014 |
|
RU2695607C2 |
